The acne challenge: Management in an age of bacterial resistance

James J. Leyden, Lawrence F. Eichenfield, Donald R. Graham, Alan R. Shalita, Diane Thiboutot

Research output: Contribution to journalReview article

Abstract

Acne vulgaris - or, more simply, acne - is the most prevalent skin disease, affecting nearly 80% of persons aged 11 to 30 years at some point in their lives.1 The condition may persist for years sometimes into middle age and later - and may result in permanent scarring and disfigurement, emotional problems, and depression. Although many treatments for acne are available, effective management has become increasingly challenging with the emergence of antibiotic- resistant strains of Propionibacterium acnes - the gram-positive anaerobe responsible for the inflammation of acne. Resistance to P. acnes is reported to have increased from "extremely rare to occasional" in the mid 1980s to 62% in referral centers in 1996.2 It is now estimated that one in four patients with acne harbors strains resistant to at least one of the major antibiotics.3 "Antibiotic therapy has been a backbone in the management of acne for many decades and probably will continue to be in the future, although, with the development of less-sensitive strains, the predictability of antibiotic therapy can no longer be assumed," stated James J. Leyden, MD, who is Professor in the Department of Dermatology at the University of Pennsylvania School of Medicine in Philadelphia. To further physician understanding of the impact of bacterial resistance in the management of acne, Dr. Leyden moderated this Medical Crossfire with a panel of leaders in the fields of dermatology, pediatrics, and infectious diseases.

Original languageEnglish (US)
Pages (from-to)30-44
Number of pages15
JournalMedical Crossfire
Volume5
Issue number1
StatePublished - Jan 15 2003

Fingerprint

Acne Vulgaris
Propionibacterium acnes
Dermatology
Anti-Bacterial Agents
Skin Diseases
Cicatrix
Communicable Diseases
Therapeutics
Referral and Consultation
Medicine
Depression
Pediatrics
Inflammation
Physicians

All Science Journal Classification (ASJC) codes

  • Health Policy

Cite this

Leyden, J. J., Eichenfield, L. F., Graham, D. R., Shalita, A. R., & Thiboutot, D. (2003). The acne challenge: Management in an age of bacterial resistance. Medical Crossfire, 5(1), 30-44.
Leyden, James J. ; Eichenfield, Lawrence F. ; Graham, Donald R. ; Shalita, Alan R. ; Thiboutot, Diane. / The acne challenge : Management in an age of bacterial resistance. In: Medical Crossfire. 2003 ; Vol. 5, No. 1. pp. 30-44.
@article{c8b1107d37e44d2a827f8689e910d05a,
title = "The acne challenge: Management in an age of bacterial resistance",
abstract = "Acne vulgaris - or, more simply, acne - is the most prevalent skin disease, affecting nearly 80{\%} of persons aged 11 to 30 years at some point in their lives.1 The condition may persist for years sometimes into middle age and later - and may result in permanent scarring and disfigurement, emotional problems, and depression. Although many treatments for acne are available, effective management has become increasingly challenging with the emergence of antibiotic- resistant strains of Propionibacterium acnes - the gram-positive anaerobe responsible for the inflammation of acne. Resistance to P. acnes is reported to have increased from {"}extremely rare to occasional{"} in the mid 1980s to 62{\%} in referral centers in 1996.2 It is now estimated that one in four patients with acne harbors strains resistant to at least one of the major antibiotics.3 {"}Antibiotic therapy has been a backbone in the management of acne for many decades and probably will continue to be in the future, although, with the development of less-sensitive strains, the predictability of antibiotic therapy can no longer be assumed,{"} stated James J. Leyden, MD, who is Professor in the Department of Dermatology at the University of Pennsylvania School of Medicine in Philadelphia. To further physician understanding of the impact of bacterial resistance in the management of acne, Dr. Leyden moderated this Medical Crossfire with a panel of leaders in the fields of dermatology, pediatrics, and infectious diseases.",
author = "Leyden, {James J.} and Eichenfield, {Lawrence F.} and Graham, {Donald R.} and Shalita, {Alan R.} and Diane Thiboutot",
year = "2003",
month = "1",
day = "15",
language = "English (US)",
volume = "5",
pages = "30--44",
journal = "Medical Crossfire",
issn = "1525-9404",
publisher = "Liberty Communication Network Inc",
number = "1",

}

Leyden, JJ, Eichenfield, LF, Graham, DR, Shalita, AR & Thiboutot, D 2003, 'The acne challenge: Management in an age of bacterial resistance', Medical Crossfire, vol. 5, no. 1, pp. 30-44.

The acne challenge : Management in an age of bacterial resistance. / Leyden, James J.; Eichenfield, Lawrence F.; Graham, Donald R.; Shalita, Alan R.; Thiboutot, Diane.

In: Medical Crossfire, Vol. 5, No. 1, 15.01.2003, p. 30-44.

Research output: Contribution to journalReview article

TY - JOUR

T1 - The acne challenge

T2 - Management in an age of bacterial resistance

AU - Leyden, James J.

AU - Eichenfield, Lawrence F.

AU - Graham, Donald R.

AU - Shalita, Alan R.

AU - Thiboutot, Diane

PY - 2003/1/15

Y1 - 2003/1/15

N2 - Acne vulgaris - or, more simply, acne - is the most prevalent skin disease, affecting nearly 80% of persons aged 11 to 30 years at some point in their lives.1 The condition may persist for years sometimes into middle age and later - and may result in permanent scarring and disfigurement, emotional problems, and depression. Although many treatments for acne are available, effective management has become increasingly challenging with the emergence of antibiotic- resistant strains of Propionibacterium acnes - the gram-positive anaerobe responsible for the inflammation of acne. Resistance to P. acnes is reported to have increased from "extremely rare to occasional" in the mid 1980s to 62% in referral centers in 1996.2 It is now estimated that one in four patients with acne harbors strains resistant to at least one of the major antibiotics.3 "Antibiotic therapy has been a backbone in the management of acne for many decades and probably will continue to be in the future, although, with the development of less-sensitive strains, the predictability of antibiotic therapy can no longer be assumed," stated James J. Leyden, MD, who is Professor in the Department of Dermatology at the University of Pennsylvania School of Medicine in Philadelphia. To further physician understanding of the impact of bacterial resistance in the management of acne, Dr. Leyden moderated this Medical Crossfire with a panel of leaders in the fields of dermatology, pediatrics, and infectious diseases.

AB - Acne vulgaris - or, more simply, acne - is the most prevalent skin disease, affecting nearly 80% of persons aged 11 to 30 years at some point in their lives.1 The condition may persist for years sometimes into middle age and later - and may result in permanent scarring and disfigurement, emotional problems, and depression. Although many treatments for acne are available, effective management has become increasingly challenging with the emergence of antibiotic- resistant strains of Propionibacterium acnes - the gram-positive anaerobe responsible for the inflammation of acne. Resistance to P. acnes is reported to have increased from "extremely rare to occasional" in the mid 1980s to 62% in referral centers in 1996.2 It is now estimated that one in four patients with acne harbors strains resistant to at least one of the major antibiotics.3 "Antibiotic therapy has been a backbone in the management of acne for many decades and probably will continue to be in the future, although, with the development of less-sensitive strains, the predictability of antibiotic therapy can no longer be assumed," stated James J. Leyden, MD, who is Professor in the Department of Dermatology at the University of Pennsylvania School of Medicine in Philadelphia. To further physician understanding of the impact of bacterial resistance in the management of acne, Dr. Leyden moderated this Medical Crossfire with a panel of leaders in the fields of dermatology, pediatrics, and infectious diseases.

UR - http://www.scopus.com/inward/record.url?scp=0037440310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037440310&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:0037440310

VL - 5

SP - 30

EP - 44

JO - Medical Crossfire

JF - Medical Crossfire

SN - 1525-9404

IS - 1

ER -

Leyden JJ, Eichenfield LF, Graham DR, Shalita AR, Thiboutot D. The acne challenge: Management in an age of bacterial resistance. Medical Crossfire. 2003 Jan 15;5(1):30-44.